ADC Therapeutics SA ROA 2019-2022 | ADCT
Current and historical return on assets (ROA) values for ADC Therapeutics SA (ADCT) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
| ADC Therapeutics SA ROA - Return on Assets Historical Data |
| Date |
TTM Net Income |
Total Assets |
Return on Assets |
| 2022-06-30 |
$-0.19B |
$0.52B |
-31.72% |
| 2022-03-31 |
$-0.20B |
$0.58B |
-34.06% |
| 2021-12-31 |
$-0.23B |
$0.62B |
-42.35% |
| 2021-09-30 |
$-0.25B |
$0.64B |
-48.70% |
| 2021-06-30 |
$-0.20B |
$0.46B |
-40.98% |
| 2021-03-31 |
$-0.26B |
$0.46B |
-54.49% |
| 2020-12-31 |
$-0.25B |
$0.51B |
-69.79% |
| 2020-06-30 |
$-0.20B |
$0.37B |
-214.97% |
| 2020-03-31 |
$-0.10B |
$0.00B |
inf% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.000B |
$0.034B |
|
ADC Therapeutics SA is a late clinical-stage oncology-focused biotechnology company. It engages in development and commercialization of antibody drug conjugates for patients suffering from hematological malignancies and solid tumors. ADC Therapeutics SA is based in LAUSANNE, Switzerland.
|
